Short interest in Predictive Oncology Inc. (NASDAQ:POAI) down 18.0%

Predictive Oncology Inc. (NASDAQ:POAI – Get Your Free Report ) saw a large drop in short interest in September. As of September 15th, there was short interest totaling 64,100 shares, a decrease of 18.0% from its August 31st total of 78,200 shares. About 1.0% of the stock’s shares are short sold. Based on an average daily trading volume of 2,700,000 shares, the short interest rate is currently 0.0 days.

The Wall Street analyst weighs in

Separately, HC Wainwright assumed coverage on shares of Predictive Oncology in a report on Monday, August 19th. They issued a “buy” rating and a $3.00 price objective for the company.

Read the latest predictive oncology stock analysis

Price performance of predictive oncology

Shares of Predictive Oncology stock traded up $0.03 during mid-day trading on Friday, reaching $0.79. The company’s stock had a trading volume of 74,319 shares, compared to its average volume of 1,550,137. The company has a 50-day moving average price of $0.97 and a 200-day moving average price of $1.39. Predictive Oncology has a 12-month low of $0.75 and a 12-month high of $4.10. The stock has a market cap of $5.24 million, a price-to-earnings ratio of -0.22 and a beta of 1.13.

Predictive Oncology (NASDAQ:POAI – Get Free Report ) last posted its earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. Predictive Oncology had a negative net margin of 802.69% and a negative return on equity of 200.06%. The company had revenue of $0.28 million for the quarter. On average, equities research analysts expect that Predictive Oncology will post -2.03 earnings per share for the current fiscal year.

About Predictive Oncology

(Get a free report)

Predictive Oncology Inc operates as a science-driven oncology drug discovery company. It offers various solutions for oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules in medicine by introducing human diversity earlier in the discovery process, with the pairing of artificial intelligence and the biobank of approximately 150,000 tumor samples.

Further reading

Receive daily Predictive Oncology news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Predictive Oncology and related companies with MarketBeat.com ‘s FREE daily email newsletter.